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Since its application in BRCA1/2-mutated cancer in a decade ago, 
synthetic lethality induced by PARPis has given renewed enthusiasm 
to developing anticancer treatments that can specifically target 
cancer cells but spare normal tissue1,2. Although different underly-
ing mechanisms have been proposed3,4, they are mostly attributed 
to critical functions of PARP in a variety of DNA-repair processes, 
including as a critical sensor of single-strand breaks (SSBs) in base-
excision repair (BER)5,6; as a mediator for restarting stalled replication 
forks of HR-mediated double-strand break (DSB) repair7–9; and as a 
means of preventing the binding of Ku proteins to DNA ends in 
non-homologous end-joining (NHEJ) pathways10. Specifically, 
inhibition of BER impairs SSB repair, which results in accumulation 
of DSBs at the replication forks during the S phase of the cell cycle. 
DNA repair and survival of PARP-inhibited cells seem to be heavily 
dependent on HR, which is compromised in cancer cells carrying 
BRCA-related mutations11–17, leading to their unique susceptibility 
to PARPi treatment. There are also alternative but not mutually exclu-
sive models in which PARPis may suppress transcriptional activity 
of PARP1,18 and/or function as poisons that result in PARP–DNA 
complex trapping and selective killing4.
In spite of its promise in breast and ovarian cancer, the clinical 
application of PARPis has not widely been translated to different 
cancers as an effective treatment, partly because mutations affecting 
DDR-associated genes are not common in other malignancies, includ-
ing AML19, which is mainly driven by mutated transcription factors 
such as AML1-ETO, PML-RAR  and MLL fusions20. The same 
chemotherapy that was developed more than half a century ago is 
still used for nearly all AML patients, with the only exception being 
acute promyelocytic leukemia (APL), which carries a PML-RAR  
fusion21. Owing to its high general toxicity, chemotherapy can usually 
only be applied to patients under age 60, leaving few or no treatment 
options for the majority of AML cases21. In addition, standard chemo-
therapy only induces less than 40% long-term complete remission and 
is mostly ineffective in patients carrying mutations in the KMT2A 
gene, which can be found in both AML and acute lymphoblastic 
leukemia (ALL)21,36. Therefore there is an urgent need to develop 
better therapeutic strategies for AML. Because specific transcriptional 
programs, including those involved in DDR, are frequently deregu-
lated by various oncogenic transcription factors, we reasoned that 
transcriptional deregulation might represent an alternative mecha-
nism that would allow the use of synthetic lethality approaches for 
effective leukemia treatments19.
RESULTS
Inhibition of PARP suppresses leukemia driven by AML1-ETO 
and PML-RARa
To explore the therapeutic potentials of targeting PARP in acute 
leukemia, we investigated the effect of olaparib, a PARPi, on 
primary mouse hematopoietic cells transformed by the most com-
mon leukemia-associated transcription factors (LATFs), including 
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Acute myeloid leukemia (AML) is mostly driven by oncogenic transcription factors, which have been classically viewed as 
intractable targets using small-molecule inhibitor approaches. Here we demonstrate that AML driven by repressive transcription 
factors, including AML1-ETO (encoded by the fusion oncogene RUNX1-RUNX1T1) and PML-RARa fusion oncoproteins (encoded 
by PML-RARA) are extremely sensitive to poly (ADP-ribose) polymerase (PARP) inhibition, in part owing to their suppressed 
expression of key homologous recombination (HR)-associated genes and their compromised DNA-damage response (DDR). In 
contrast, leukemia driven by mixed-lineage leukemia (MLL, encoded by KMT2A) fusions with dominant transactivation ability is 
proficient in DDR and insensitive to PARP inhibition. Intriguingly, genetic or pharmacological inhibition of an MLL downstream 
target, HOXA9, which activates expression of various HR-associated genes, impairs DDR and sensitizes MLL leukemia to PARP 
inhibitors (PARPis). Conversely, HOXA9 overexpression confers PARPi resistance to AML1-ETO and PML-RARa transformed cells. 
Together, these studies describe a potential utility of PARPi-induced synthetic lethality for leukemia treatment and reveal a novel 
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AML1-ETO, PML-RAR , MLL-AF9 and E2A-PBX, using the retro-
viral transduction/transformation assay (RTTA)22–25. Whereas a con-
centration of up to 1 M olaparib exhibited minimal effects on normal 
bone marrow, it had a notable effect on transformed primary cells. 
PARPi significantly suppressed the colony-forming ability of cells 
transformed by AML1-ETO or PML-RAR  by about 90%, although it 
exhibited little impact on MLL-AF9– or E2A-PBX–transformed cells 
(Fig. 1a,b and Supplementary Fig. 1a–d). To confirm the specificity 
of the drug, we also reported very similar and selective leukemia-sup-
pressive effects using a different PARPi, veliparib (Supplementary 
Fig. 1e,f). To show that PARP1 was the major molecular target for the 
observed phenotype upon PARPi treatment, two independent Parp1-
targeting shRNAs (Supplementary Fig. 1g,h) were used to deplete 
Parp1 in the RTTA. Consistently, both Parp1-targeting shRNAs sig-
nificantly suppressed the colony-forming ability of cells transformed 
by AML1-ETO or PML-RAR , but not those transformed by E2A-
PBX and MLL-AF9 (Fig. 1c,d and Supplementary Fig. 1i).
To investigate the effects of PARPi on the corresponding human 
leukemias, we used patient-derived leukemic cell lines carrying 
AML1-ETO (Kasumi), mutated PML-RAR  that is resistant to 
standard all-trans retinoic acid (ATRA) treatment (NB4-LR2)25, or 
MLL-AF9 (THP1) for the inhibitor studies. Analogously to the mouse 
models, PARPi reduced the colony-forming ability of Kasumi and 
NB4-LR2 cells, but not THP1 cells (Fig. 1e,f). To further demon-
strate potential in vivo efficacy, these cells were xenotransplanted into 
immunocompromised mice and subjected to the PARPi treatment. 
Despite being used as a monotherapy, olaparib significantly delayed 
the disease onset driven by AML1-ETO from a median survival of 
55 d to 102 d (Fig. 1g, Supplementary Fig. 1j,m, and Supplementary 
Table 1). Notably, olaparib as a single agent could also effectively 
suppress disease onset induced by ATRA-resistant APL cells (Fig. 1h, 
Supplementary Fig. 1k,n, and Supplementary Table 1). In contrast, 
PARPi had no effect on the survival of a xenograft mouse model 
transplanted with THP1 cells (Fig. 1i, Supplementary Fig. 1l,o, and 
Supplementary Table 1). To further substantiate these findings, we 
also observed very similar differential in vitro PARPi responses from 
primary AML patient samples carrying the corresponding transloca-
tion fusions (Supplementary Fig. 1p,q). Together, these results reveal 
the potential therapeutic utility of PARPis in different subtypes of 
leukemia driven by specific LATFs, including AML1-ETO–driven 
leukemia and ATRA-resistant APL26.
PARPi treatment induces differentiation and senescence
Although PARPi can generally slow leukemic cell growth, PARPi 
treatment of AML1-ETO– and PML-RAR –transformed mouse cells 
resulted in their morphological differentiation into monocytic and 
granulocytic lineages (Fig. 2a,b and Supplementary Fig. 2a–d), which 
is consistent with recent observations of leukemic differentiation 
induced by excessive DNA damage27, suggesting that differential DDR 
may underlie the contrasting PARPi responses. PARPi treatment was 
also accompanied by cell cycle G1 arrest (Fig. 2c and Supplementary 
Fig. 2e), upregulation of Tp53 (also known as p53), Cdkn1a (also 
known as p21) (Fig. 2d,e) and Cdkn2a (also known as p16) expression 
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Figure 1 PARPi targets AML1-ETO– and PML-RAR –transformed leukemic cells in vitro and in vivo. (a) Relative number of colonies of leukemic cells 
surviving after treatment with olaparib, a PARPi. The number of colonies was acquired after 7 d of olaparib treatment in each round and data was 
normalized against the vehicle control. Data are mean  s.d. of six independent experiments. One-way analysis of variance (ANOVA) test was performed; 
***P < 0.001. (b) Representative colony morphology with or without olaparib treatment. (c) Relative number of colonies of oncogene-induced leukemic 
cells transduced either with empty vector or shRNAs (shParp1#A and shParp1#D) targeting Parp1. The number of colonies was normalized against 
empty vector control. Data are mean  s.d. of three independent experiments. Two-way ANOVA test was performed; *P < 0.05, **P < 0.01, ***P < 0.001.  
(d) Representative colony morphology of leukemic cells transformed by the indicated oncoproteins and transduced with empty vector or Parp1-targeting 
shRNAs (shParp1#A and shParp1#D). (e) Relative number of colonies of the human leukemic cell lines Kasumi (AML1-ETO), NB4-LR2 (PML-RAR ) 
and THP1 (MLL-AF9), grown in methylcellulose for 7 d. The number of colonies after PARPi treatment was normalized against the untreated control. 
Data are mean  s.d. of three independent experiments. One-way ANOVA test was performed; ***P < 0.001. (f) Representative colony morphology of 
human leukemic cell lines treated with PARPi. (g) Kaplan-Meier survival curve of NSG mice transplanted with Kasumi cell lines treated with olaparib or 
vehicle (DMSO). (h) Kaplan-Meier survival curve of NSG mice transplanted with NB4-LR2 cells treated with olaparib or vehicle (DMSO). (i) Kaplan-Meier 
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underwent significant senescence upon PARPi treatment (Fig. 2g,h). 
PARPi treatment also induced apoptosis of PML-RAR –transformed 
cells (Fig. 2i and Supplementary Fig. 2f). In contrast, none of these 
effects were observed in E2A-PBX– or MLL-AF9–transformed 
cells despite a small upward trend in differentiation and apoptosis 
(Fig. 2a–i). In accordance with the mouse data, PARPi could effec-
tively induce senescence and apoptosis in Kasumi and NB4-LR2 cells 
but not THP1 cells (Supplementary Fig. 2g–i); and increased differ-
entiation of primary AML cells carrying AML1-ETO and PML-RAR  
fusions but not MLL fusions (Supplementary Fig. 2j–l). These results 
consistently suggest a specific requirement of PARP function in cells 
transformed by AML1-ETO and PML-RAR .
AML1-ETO– and PML-RARa–transformed cells show  
inherent DDR defects
Although the general rationale behind the PARPi sensitivity is a defect 
in DDR3,4,15,16,28, PARP also has transcriptional functions involved 
in gene regulation1,18. After failing to detect direct biochemical inter-
action (Supplementary Fig. 3a and M.T.E., T.K.F., N.M., J.G. and 
C.W.E.S., unpublished mass spectrometry data) and transcriptional 
regulation (Supplementary Fig. 3b–e) between PARP1 and any of the 
studied leukemia fusion proteins, we examined the kinetics of the DDR 
in primary transformed cells by analyzing Ser139-phosphorylated 
H2AX foci, which are considered to be an early response to 
DSBs29. With the exception of E2A-PBX, untreated AML1-ETO–, 
PML-RAR – and MLL-AF9–transformed cells displayed significant 
levels of H2AX DNA damage foci, indicative of ongoing DNA dam-
age or replication stress (Fig. 3a,b and Supplementary Fig. 3f). Upon 
PARPi treatment, both PARPi-insensitive and PARPi-sensitive cells 
showed further induction of H2AX foci (Fig. 3c and Supplementary 
Fig. 3g–k), suggesting that PARPi induced DNA damage regardless 
of the oncoprotein fusions. Then we investigated recruitment of the 
recombinase to DNA damage sites, as a readout of HR efficiency30,31. 
Upon PARPi treatment for 6 h, E2A-PBX or MLL-AF9 cells were able 
to efficiently form RAD51 foci, which then returned to basal levels 
after the repair in 24 h (Fig. 3c,d and Supplementary Fig. 3g–j,l). In 
contrast, little RAD51 recruitment was observed in AML1-ETO or 
PML-RAR  cells, in which around 80% showed H2AX and RAD51 
foci ratio greater than 2 (Fig. 3e), indicating their HR-deficient 
nature. The observed differential HR deficiency associated with 
PARPi treatment is unlikely to be due to different cell cycle status 
of these cells, as PARPi exhibited no significant effect on cell cycle 
progression in the first 24 h (Supplementary Fig. 3m) when these 
assays were performed. To further extend our findings to human 
disease, we consistently observed higher levels of DNA damage in 
Kasumi and NB4-LR2 cells (Supplementary Fig. 3n,o), which also 
failed to effectively induce RAD51 foci upon PARPi treatment, as 
compared with THP1 cells (Supplementary Fig. 3p–r).
Next, we investigated and revealed a decreased expression of key 







































































































































































































































































































































































































































































Figure 2 PARPis induce differentiation, senescence, and apoptosis of AML1-ETO– and  
PML-RAR –transformed leukemic cells. (a) May-Grunwald Giemsa staining of leukemic  
cells upon treatment with PARPi. (b) Quantification of morphologically differentiated cells  
in a. Data are mean ± s.d. One-way ANOVA was performed; ***P < 0.001. (c) Cell cycle  
analysis of leukemic cells after 48–72 h of continuous PARPi treatment. Data are mean  s.d.  
of three independent experiments. One-way ANOVA was performed; *P < 0.05. (d–f) Expression  
of Tp53 (d), Cdkn1a (e) and Cdkn2a (f) in the indicated transformed cells after continuous  
PARPi treatment. Expression of the target genes was normalized against Gapdh (2- CT).  
Data are mean  s.d. of three independent experiments. Unpaired t-test was performed;  
*P < 0.05, **P < 0.01, ***P < 0.001. (g) Representative image from three independent  
experiments showing -galactosidase staining of primary transformed cells after 24 h and  
48 h of PARPi treatment. (h) Quantification of percentage of -galactosidase positive cells.  
Data are mean  s.d. of three independent experiments. One-way ANOVA test was  
performed; ***P < 0.001. (i) Quantification of percentage of annexin V+ propidium iodide (PI)+ and annexin V+PI− cells upon PARPi treatment at 24 h 
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Figure 3 AML1-ETO– and PML-RAR –transformed cells show a defect in the HR pathway and accumulate DNA damage in response to PARPi treatment. 
(a) Immunofluorescence microscopy of H2AX foci in untreated primary transformed mouse cells (representative cells). (b) Quantification of the 
percentage of cells with >6 H2AX foci  s.d. One-way ANOVA test was performed; **P < 0.01, ***P < 0.001. (c) Time-course analysis of PARPi induced 
H2AX and RAD51 foci by immunofluorescence upon continuous PARPi treatment (representative cells). (d) Quantification of percentage of RAD51 
positive cells upon PARPi treatment at the indicated time point. Data are mean ± s.d. One-way ANOVA test was performed;*P < 0.05 ***P < 0.001.  
(e) The percentage of cells with H2AX/RAD51 ratio >2 is shown, data are mean ± s.d.; one-way ANOVA test was performed; *P < 0.05. (f) qPCR showing 
relative expression of Rad51, Brca1, Brca2, Atm, Mcm9 and Rpa1 in primary mouse cells transformed by the indicated oncoproteins. Data are mean ± s.d. 
One-way ANOVA was performed; *P < 0.05, **P < 0.01, ***P < 0.001. (g) Box plots showing the relative microarray expression of RAD51, ATM, BRCA1, 
BRCA2, MCM9 and RPA1 in AML patients carrying the AML1-ETO or PML-RAR  translocations (APL) or MLL fusions. Paired t-test was performed;  
*P < 0.05, **P < 0.01, ***P < 0.001. (h) Western blot showing the relative expression levels of RAD51 and BRCA2 in mouse cells transformed by the 
indicated oncoproteins. Numbers represents relative band intensity normalized to -actin. (i) Colony-forming efficiency as an indicator of DSB repair  
is shown (left), as is the percentage of misrepair (right). Data are mean  s.e.m. of three independent experiments. One-way ANOVA was performed;  
*P < 0.05, ***P < 0.001. (j) Efficiency of HR-mediated repair of I-SceI–induced DSB in U2OS cells with a chromosomally integrated direct repeat-GFP 
reporter (U2OS-DR-GFP) transfected with I-SceI, dsRFP and the indicated oncoproteins or vector control. Data are mean  s.d. of three independent 
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and PML-RAR  mouse models (Fig. 3f). By analyzing the expression 
array data of these genes in two different human AML cohorts32,33, 
we consistently observed very similar suppression of these HR media-
tors in human AML1-ETO– and PML-RAR −associated leukemia, as 
compared with MLL-rearranged leukemia (Fig. 3g, Supplementary 
Fig. 3s and Supplementary Table 2). We also further validated the 
protein expression of key HR mediators, RAD51 and BRCA2, using 
mouse primary leukemic cells transformed by the corresponding 
fusions (Fig. 3h). To assess the direct effect of these fusions on DNA 
repair, we performed both a plasmid end-joining assay34 and an HR 
reporter assay35. Nuclear extracts from E2A-PBX– and MLL-AF9–
transformed cells could efficiently repair DSBs, and they produced 
significantly higher total numbers of colonies carrying the repaired 
plasmid than did AML1-ETO– and PML-RAR –transformed cells. 
Moreover, in contrast to E2A-PBX– and MLL-AF9–transformed cells, 
most of the end repairs by nuclear extracts from AML1-ETO– or PML-
RAR –transformed cells were mismatched (Fig. 3i). Consistently, we 
also observed significant suppression of HR efficiency upon expres-
sion of AML1-ETO or PML-RAR , as opposed to a small and signifi-
cant increase in HR upon expression of MLL-AF9 (Fig. 3j). Therefore, 
these data indicate that leukemic cells driven by AML1-ETO and 
PML-RAR  had a reduced ability to repair DSB and that the repairs 
were accompanied by an increased error rate, which may form the 
basis for their increased PARPi sensitivity.
Induction of HOXA9 by MLL fusions modulates PARPi sensitivity
In contrast to AML1-ETO and PML-RAR 20,24, MLL-fusion pro-
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Figure 4 HOXA9 modulates  
sensitivity to PARPi.  
(a) Relative colony number  
of primary transformed cells  
from wild-type or Hoxa9−/−  
(Hoxa9 ko) background  
surviving after PARPi  
treatment. The number  
of colonies was normalized  
against the wild-type control.  
Data represents mean  s.d. of  
five independent experiments.  
Two-way ANOVA test was performed; **P < 0.01, ***P < 0.001.  
(b) Representative colony morphology of cells shown in a.  
(c) May-Grunwald Giemsa staining of cells generated with  
Hoxa9−/− mice. (d) -galactosidase staining of cells in c.  
(e) Quantification of percentage of -galactosidase positive  
cells upon 48 h of PARPi treatment. Data are mean  s.d. of  
two independent experiments. Unpaired t-test was performed;  
*P < 0.05, ***P < 0.001. (f,g) Kaplan-Meier survival curves of  
C57Bl/6 mice transplanted with MLL-AF9 leukemic cells  
generated in wild-type (pooled from three independent  
experiments) (f) and Hoxa9−/− (pooled from three independent  
experiments) (g) backgrounds, respectively. (h) Relative number of colonies of primary transformed cells overexpressing HOXA9 in the presence of 
PARPi (left), and representative images of colony morphology (right). The number of colonies surviving to 7 d of incubation with PARPi was normalized 
against the vehicle control. Data are mean  s.d. of three independent experiments. Two-way ANOVA test was performed; ***P < 0.001. (i) May-
Grunwald Giemsa staining of primary transformed cells overexpressing HOXA9. (j) Representative -galactosidase staining (left) and quantification  
of the percentage of -galactosidase–positive cells upon PARPi treatment for 24 and 48 h (right). Data represents means of two independent 
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critical downstream genes, including the homeodomain transcription 
factor HOXA9 (refs. 20,36,37), which was previously identified as 
one of the single most critical independent prognostic factors asso-
ciated with poor AML treatment response38, and the suppression of 
which has been linked to the drug-resistant phenotype in glioblas-
toma39,40. Consistently, we could observe specific and differential 
expression of Hoxa9 by MLL fusion in our mouse models and human 
samples (Supplementary Fig. 4a–c). Thus we hypothesized that the 
PARPi resistance exhibited by MLL-AF9–transformed cells might be 
dependent on the ability of MLL-AF9 to activate Hoxa9. To this end, 
we assessed the functional requirement of Hoxa9 in conferring PARPi 
resistance in MLL-AF9 cells using a Hoxa9-knockout mouse model. 
Consistent with previous reports24,41,42, knockout of Hoxa9 had a 
relatively modest effect on MLL-AF9–transformed cells despite a 
more mature phenotype and a slightly reduced colony-forming ability, 
as compared with their wild-type counterparts41 (Fig. 4a–c and 
Supplementary Fig. 4d–g). Notably, ablation of Hoxa9 expression 
sensitized MLL-AF9–transformed cells, but not HOXA9-independent 
E2A-PBX–transformed control cells24,43 to PARPi treatment, 
which resulted in a significant suppression of colony-forming abil-
ity but inductions of differentiation and senescence (Fig. 4a–e and 
Supplementary Fig. 4d–f). This is consistent with the role of Hoxa9 
suppressing cellular senescence24, a common endpoint of excessive 
DNA damage. We then tested whether suppression of Hoxa9 sensi-
tizes advanced-stage MLL leukemia to PARPi treatment in vivo by 
using MLL-AF9 full-blown leukemic cells harvested from primary 
transplanted mouse. As expected, olaparib did not have any signifi-
cant effect on mice transplanted with wild-type MLL-AF9 leukemic 
cells. In contrast, although Hoxa9-deficient MLL-AF9 cells could effi-
ciently induce leukemia, they were highly sensitive to PARPi treat-
ment, which significantly delayed the disease latency (Fig. 4f,g and 
Supplementary Fig. 4h; Supplementary Tables 3 and 4). To further 
demonstrate the role of HOXA9 in mediating PARPi resistance, we 
also used a gain-of-function approach by overexpressing HOXA9 in 
PARPi-sensitive AML1-ETO– and PML-RAR –transformed cells. As 
expected, cells transduced with the vector control remained sensitive 
to PARPi. Forced expression of HOXA9 conferred PARPi resistance 
to AML1-ETO–and PML-RAR –transformed cells without affecting 
the expression of the fusions (Fig. 4h–j and Supplementary Fig. 4i,j). 
Together with the loss-of-function data, these results strongly suggest 
Hoxa9 as a key player in mediating PARPi resistance.
HOXA9 activates HR gene expression and DNA repair
Upon HOXA9 overexpression, we observed significant recruitment of 
RAD51 to DNA damage foci in AML1-ETO– and PML-RAR – but 
not E2A-PBX– or MLL-AF9–transformed cells, which already showed 
efficient recruitment of RAD51 (Fig. 5a–b). Conversely, suppression 
of Hoxa9 expression resulted in a significant impairment of RAD51 
recruitment in MLL-AF9 transformed cells (Fig. 5c–d), leading to the 
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Figure 5 HOXA9 modulates PARPi sensitivity. (a) Immunofluorescence microscopy of PARPi induced H2AX and RAD51 foci in wild-type and  
HOXA9-overexpressing cells (representative cells). (b) Quantification of the percentage of cells with >6 H2AX or RAD51 foci in wild-type and  
HOXA9-overexpressing cells. Data are mean ± s.d. Two-way ANOVA test was performed; **P < 0.01, ***P < 0.001. (c) Immunofluorescence 
microscopy of PARPi-induced H2AX and RAD51 foci in MLL-AF9 cells generated in wild-type and Hoxa9−/− (Hoxa9 ko, Hoxa9 knockout) background 
(representative cells). (d) Quantification of percentage of cells with >6 H2AX or RAD51 foci in wild-type and Hoxa9−/− cells. Data are mean ± s.d.  
Two-way ANOVA test was performed; *P < 0.05. (e) Gene Set Enrichment Analysis (GSEA). Genes associated with homologous recombination pathway 
are enriched in the transcriptional profile of mouse myeloblasts overexpressing HOXA9. NES, normalized enrichment score; FDR, false discovery rate. 
(f) RT-qPCR showing expression levels of Rad51 in primary transformed mouse cells overexpressing HOXA9. Data are mean ± s.d. Unpaired two-tailed 
t-test was performed; *P < 0.05. (g) Relative expression of Rad51 in MLL-AF9–transformed cells generated in wild-type and Hoxa9−/− background.  
Data are mean ± s.d. Unpaired two-tailed t-test was performed; ***P < 0.001. (h) Western blot analysis of RAD51 and BRCA2 in MLL-AF9–transformed 
cells in wild-type, Hoxa9−/−and Ctnnb1−/− background. -actin was used as a loading control. (i) Bar chart shows efficiency of HR-mediated repair 
of I-SceI-induced DSBs in U2OS-DRGFP cells transfected with I-SceI, dsRFP, and HOXA9-expressing or HOXA9-targeting shRNA plasmids. Data is 
normalized to empty vector or scrambled shRNA. U2OS-DRGFP cells were subject to 5 gray (Gy) radiation 24 h after HOXA9 overexpression.  
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Figure 6 Combined PARPi and GSK3i treatment impairs in vivo survival of MLL leukemia cells. (a) Relative number of colonies (left) and c-Myb 
expression (right) of pre-LSCs after treatment with DMSO, PARPi, LiCl or a combination of PARPi and LiCl. Data are mean ± s.d. One-way ANOVA was  
performed; ***P < 0.001. wt, wild type. (b) Relative number of colonies (left) and c-Myb expression (right) of LSCs after treatment with DMSO, PARPi, 
LiCl or a combination of PARPi and LiCl. Data are mean ± s.d. One-way ANOVA was performed; **P < 0.01, ***P < 0.001. (c) May-Grunwald Giemsa  
staining of MLL-AF9 pre-LSCs and LSCs. (d) The percentage of pre-LSC and LSCs undergoing differentiation characterized by morphology (top) and  
nitro blue tetrazolium (NBT)-positive cells (bottom) after 4 d of treatment with vehicle (DMSO), PARPi, LiCl or a combination of PARPi and LiCl. Data  
are mean ± s.d. One-way ANOVA was performed; *P < 0.05, **P < 0.01, ***P < 0.001. (e) Kaplan-Meier survival curves of C57Bl/6 mice transplanted 
with MLL-AF9 LSCs pre-treated in liquid culture for 3 d before transplantation. Duration of in vivo treatment is indicated in gray. (f) Relative fold  
change in cell numbers of primary patients-derived leukemic cells carrying MLL-rearrangements [patient ID nos. AML1 (top) and AML2 (bottom)]  
after treatment with PARPi, LiCl, a combination of PARPi and LiCl, or vehicle. Data are mean ± s.d. One-way ANOVA test was performed; *P < 0.05;  
**P < 0.01; ***P < 0.001. (g) May-Grunwald Giemsa staining of human MLL samples. (h) The percentage of primary leukemic cells undergoing  
differentiation characterized by morphology (left) and by NBT-positive cells (right). Data are mean ± s.d. One-way ANOVA was performed; **P < 0.01. 
(i) Images showing the tumor burden of NSG mice transplanted with primary patient-derived leukemic cells carrying MLL-rearrangement after treatment 
with vehicle (DMSO), olaparib, Li2CO3 or a combination of olaparib and Li2CO3. (j) Kaplan-Meier survival curves of NSG mice transplanted with  
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To this end, we analyzed the expression array data of known HOXA9 
downstream targets in primary transformed myeloid cells44,45. This 
revealed that genes involved in DNA repair were significantly enriched 
in HOXA9-responsive gene sets (Fig. 5e, Supplementary Fig. 5a,b 
and Supplementary Table 2), which was also confirmed by RT-qPCR 
using wild-type and Hoxa9-knockout MLL-AF9–transformed cells 
(Supplementary Fig. 5c). Among them were key HR-related genes 
including Rad51 (refs. 12,30,31), a fact that was further validated in the 
primary transformed cells by both HOXA9 -overexpression (Fig. 5f) 
and Hoxa9-knockout approaches (Fig. 5g and Supplementary Fig. 5d). 
Consistently, the expression of RAD51 and BRCA2 proteins were 
significantly diminished in the absence of Hoxa9 (but not Ctnnb1−/− 
control) (Fig. 5h). Finally, to demonstrate a direct involvement of 
HOXA9 in DDR, HR-reporter assays further revealed enhanced HR 
efficiency by HOXA9 overexpression as opposite to a compromised 
HR response with HOXA9 suppression (Fig. 5i). These data strongly 
suggest that HOXA9 confers PARPi-resistance in part by activating 
DDR transcriptional programs.
Targeting PARPi-resistant AML with a combination approach
Although there is not yet a chemical inhibitor that can directly target 
HOXA9, inhibitors are available to suppress its regulators and essen-
tial co-factors, including GSK3, which mediates the phosphorylation 
of CREBBP (CREB binding protein, also known as CBP), which is 
required for HOX transcriptional functions46. We and others have pre-
viously shown that GSK3 inhibitors (GSKis), such as LiCl and Li2CO3, 
were effective in suppressing the transcriptional activity of HOXA9 
and targeting MLL pre-leukemic stem cells (pre-LSCs), but not the 
advanced-stage MLL-LSCs that acquired resistance in part because of 
the activation of canonical Wnt/ -catenin pathways, and which were 
capable of inducing leukemia with a much shorter latency23,46,47. To 
further explore the potential application of PARPi on MLL leukemia, 
we assessed the effect of PARPi in combination with GSK3i, on both 
MLL pre-LSC– and MLL-LSC–enriched populations that exhibited 
contrasting GSKi sensitivity and disease latency23. As expected, the 
application of a previously-defined optimal concentration of LiCl 
(refs. 23,46,47) significantly suppressed the colony-forming ability 
of MLL pre-LSCs, but not MLL-LSCs (Fig. 6a,b and Supplementary 
Fig. 6a–c). Notably, combining LiCl with PARPi led to further inhibi-
tion of MLL pre-LSCs, which inversely correlated with transcriptional 
activity of HOXA9 as assessed by the expression of its downstream 
target, c-Myb (Fig. 6a–b). Of further note, whereas individual PARPi 
or LiCl treatment was ineffective on MLL-LSCs, the combination of 
the two treatments dramatically suppressed growth and induced dif-
ferentiation of MLL-LSCs (Fig. 6b–d). To further demonstrate the in 
vivo efficacy, pretreated MLL-LSCs were transplanted into syngeneic 
mice and subjected to treatment with olaparib, Li2CO3, or the combi-
nation of the two. As expected, mice transplanted with control MLL-
AF9 cells succumbed to leukemia within 8 weeks. PARPi or GSK3i 
treatment alone did not significantly extend the survival; notably, the 
combined PARPi and GSK3i treatment suppressed leukemia develop-
ment, and all the mice survived throughout the experiment (Fig. 6e, 
Supplementary Fig. 6d,e, and Supplementary Table 5).
To investigate whether a similar treatment could also be effective in 
the corresponding human leukemia, we first used THP1 cells that were 
mostly refractory to olaparib and showed little effect when treated 
with LiCl. However in combination, LiCl could sensitize PARPi-
resistant THP1 cells to the PARPi treatment, resulting in significant 
growth suppression and differentiation (Supplementary Fig. 6f,g). 
Then we performed the same treatments on two independent primary 
human AML samples carrying MLL-fusions (i.e., patient ID nos. 
AML1 and AML2). Whereas limited inhibition resulted from 
individual treatments, combination treatments showed consist-
ent synergistic effects in suppressing growth and promoting dif-
ferentiation of primary MLL leukemic cells from both patients 
(Fig. 6f–h). Finally, to further demonstrate the in vivo treatment effi-
cacy, we labeled cells from patient AML1 with a luciferase reporter 
prior to their transplantation into NSG mice for drug treatment. By 
in vivo imaging, we observed a rapid disease development as early 
as 4 weeks after transplant in the untreated control. We observed a 
similar rate of disease progression in cohorts receiving single-drug 
treatments, although the Li2CO3-treated group exhibited an even 
faster rate of leukemic growth (Fig. 6i and Supplementary Fig. 6h). 
In contrast, PARPi and Li2CO3 combination treatment significantly 
prohibited leukemic growth in vivo (Fig. 6i and Supplementary 
Fig. 6h). After long-term disease development, mice that received 
single-drug treatments succumbed to leukemia with a similar pheno-
type and disease latency as the control group. Notably, the combina-
tion treatment significantly suppressed leukemia development, and 
none of the mice treated with combination therapy succumbed to 
leukemia throughout the observation period (Fig. 6j, Supplementary 
Fig. 6i,j and Supplementary Table 6). Together, these independent 
results from mouse and primary human xenograft models provide 
the first proof-of-principle pre-clinical evidence for a novel effective 
therapeutic strategy based on a combined PARPi and GSK3i treatment 
for MLL leukemia.
DISCUSSION
In spite of the lack of genetic mutations directly affecting DDR-asso-
ciated genes, we provide molecular and preclinical data showing the 
potential utility of PARPi-mediated selective killing of leukemic cells car-
rying specific oncogenic transcription factors (Supplementary Fig. 7). 
In addition to the discovery of strong PARPi sensitivity in leukemic 
cells driven by AML1-ETO and PML-RAR , which suppress DDR48–52, 
we also demonstrate for the first time that HOXA9, an independent 
poor prognostic factor in AML38 and a key downstream target of 
MLL-fusions53, can activate DDR pathways and allow leukemia cells 
to overcome PARPis. This finding may also in part explain the previ-
ously reported S-phase checkpoint dysfunction of MLL-rearranged 
cells that show radio-resistant DNA synthesis and chromatid-type 
genomic abnormalities54. Emerging evidence suggests that various 
HOX proteins may be involved in DNA repair55,56. HOXB7 interacts 
with PARP-1 and the DNA-PK-Ku80-Ku70 complex–enabling NHEJ 
pathway55, whereas HOXB9 promotes HR by inducing TGF- , which 
in turn enhances ataxia telangiectasia–mutated (ATM) activation 
and ATM-dependent response in breast cancer cell lines56. Our data 
indicate that HOXA9 mediates expression of critical DDR-related 
genes to stimulate an HR response to PARPi treatment. Consistent 
with its putative role in mediating drug-resistance in glioma43,44, 
we further demonstrate that HOXA9 overexpression rescues AML1-
ETO– and PML-RAR –transformed cells from PARPi treatment, 
whereas HOXA9 suppression makes MLL-AF9–transformed cells 
sensitive to PARPi, revealing a novel function of HOXA9 in govern-
ing PARPi resistance in AML.
In line with a classical model of DDR barrier in cancer develop-
ment57, a recent study by Takacova et al.58 demonstrated that inac-
tivation of the DDR barrier through ATM and ataxia telangiectasia 
and Rad3-related (ATR) inhibitors accelerated leukemia driven by a 
tamoxifen-inducible MLL-fusion58. In contrast, Santos et al.59 have 
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genes such as MLL4, ATM or BRCA1, instead of accelerating MLL-
driven leukemogenesis, induced leukemic differentiation. These 
results suggest dual roles of the key DDR players, such as ATM, in 
promoting and suppressing MLL-leukemia, which may be dosage and 
context dependent. Notably, HOXA9, which drives leukemic growth 
and PARPi resistance, is largely dispensable for normal develop-
ment24,42,60, highlighting its potential as a therapeutic target. As a 
proof of principle, we further demonstrate that the combined use of 
PARPi together with GSK3i, which targets the transcriptional func-
tion of HOXA9 (refs. 23,46,47), can achieve selective killing of oth-
erwise PARPi-resistant MLL leukemia, revealing a novel venue for 
overcoming PARPi resistance in leukemia (Supplementary Fig. 7).
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Retroviral transduction/transformation assay (RTTA). RTTA was performed 
on primary mouse hematopoietic cells as described22. c-Kit–positive progeni-
tor cells were isolated from wild-type Ly5.1 mouse bone marrow, and cultured 
overnight in R10 medium (RPMI 1640 containing 10% FCS, 100 U/ml penicil-
lin and 100 g/mL streptomycin) supplemented with 20 ng/ml stem cell factor 
(SCF), 10 ng/ml interleukin (IL)-3, and 10ng/ml IL-6. Transduction using 
concentrated viral supernatant expressing the oncogene of interest was carried 
out by centrifugation (spinoculation) at 800g at 32 °C for 2 h in the presence of 
5 g/ml polybrene (Sigma-Aldrich). Cells were subsequently plated in 1% 
methylcellulose medium (M3231; Stem Cell Technologies) containing 20 ng/ml 
SCF, 10 ng/ml IL-3, 10 ng/ml IL-6 and 10 ng/ml granulocyte macrophage 
colony-stimulating factor (GM-CSF) and appropriate selection antibiotic. 
Colonies were counted after 7 d of culture and re-plated every 6–7 d at 5 × 103–
1.5 × 104 cell density. Re-plating was performed weekly to generate primary cell 
lines for further analysis. After the third or fourth round of plating, cells were 
cultured in R20/20 medium (RPMI 1640, 20% FCS, 20% WEHI-conditioned 
medium, 2 mM l-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin) 
supplemented with 20 ng/ml SCF, 10 ng/ml IL-3, and 10 ng/ml IL-6 to establish 
cell lines. All recombinant mouse cytokines were from Peprotech.
Cell culture. NB4-LR2 and THP1 cell lines were cultured in RPMI (Invitrogen) 
supplemented with 10% selected FBS (R10), 2 mM L-glutamine. The Kasumi cell 
line was cultured in RPMI-HEPES modified (Sigma) supplemented with 20% 
selected FBS and 2 mM l-glutamine (R20). Cell lines were validated by qPCR for 
their respective oncogenes. NIH3T3 and GP2 cell line was cultured in DMEM 
(Invitrogen) supplemented with 10% selected FBS and 2 mM l-glutamine. 
Human primary AML cells were cultured in IMEM (Invitrogen) supplemented 
with 10% PBS, 2 mM l-glutamine, 10 ng/ml each of the human cytokines IL3, 
IL6, SCF, FLT3 ligand, and TPO. Cells were kept at 37 °C and 5% CO2. Use 
of human primary cells was approved by King’s College London’s local ethics 
committee and patient consent was obtained.
In vitro drug treatment. Most of the inhibitor studies on mouse cells were car-
ried out by plating 3–5 × 103 cells in 1% methylcellulose medium containing 
20 ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml IL-6 and 10 ng/ml GM-CSF in the 
presence of 1 M olaparib (LC Laboratories), 1 M veliparib (Abbott) or 8 mM 
LiCl (Sigma) at the concentrations as indicated in the Results section. Colonies 
were scored 6–7 d after plating. For other in vitro studies, mouse leukemic cells 
and primary AML cell lines were subjected to continuous olaparib (1 M) 
or LiCl (8 mM) treatment in liquid culture for the duration as indicated in 
the figures or figure legends. For human leukemic cell lines, experiments were 
performed as described above with 5 M olaparib.
Flow cytometric analysis. Flow cytometry analyses of mouse leukemic cells for 
both in vitro and in vivo experiments were performed as previously described61 
using mouse-specific anti-CD11b (Mac-1,clone M1/70), anti-Gr1 (clone 
RB6-8C5), anti-c-Kit (clone 2B8), anti-CD45.1 (clone A20) and anti-CD45.2 
(clone 104) antibodies from BioLegend. For humanized mouse model, the 
engrafted human donor cells were analyzed using anti-human CD45 (clone 
H130) and CD33 (clone WM53). All antibodies are used at a dilution of 1:200.
Cell cycle analysis. For each assay, 105 cells were collected, washed in PBS and fixed in 
70% cold ethanol. After re-hydration with PBS and centrifugation at 500g for 5 min, 
the cells were incubated with a solution of PBS containing 1% FCS, 40 g/ml 
RNase and 500 g/ml propidium iodide solution (Sigma-Aldrich) in the dark for 
30 min at 37 °C. Samples were then analyzed at the FACS LSRII (BD Biosciences). 
DNA peaks were analyzed with FACS Diva software (BD Biosciences).
Annexin V staining. For each assay, 105 cells were collected, washed in PBS and 
re-suspended in annexin V binding solution (25 mM HEPES, 140 mM KCl, 2.5 mM 
CaCl2, pH 7.2). After centrifugation at 500g for 5 min, the cells were incubated 
with the annexin V binding solution containing 0.25 g/ml mouse anti-annexin 
V–FITC (BioLegend, 640906) and 1 g/ml propidium iodide (Sigma) in the 
dark for 30 min at 4 °C. Samples were then washed in PBS and analyzed with the 
FACS LSRII (BD Biosciences) with FACS Diva software (BD Biosciences).
b-Galactosidase staining. Cells were cytospun onto a glass slide at 400g for 5 min 
and then fixed for 10 min with 2% formaldehyde and 0.2% glutaraldehyde 
(Sigma-Aldrich). Cells were then washed with PBS, and then incubated at 
37 °C for at least 2 h with a staining solution (30 mM citric acid/phosphate buffer, 
5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6, 150 mM NaCl, 2 mM MgCl2, 1 mg/ml 
X-Gal) (All reagents from Sigma-Aldrich)62. Cells were counted in at least five 
fields for each slide, for a total of over 100 cells. The percentage of senescent cells 
was calculated by the percentage of the number of blue cells in the field.
Immunofluorescence staining of gH2AX and RAD51. Cells were cytospun 
onto a glass slide at 400g for 5 min and then fixed for 30 min in 4% PFA and 
permeabilized and blocked in 0.8% Triton X-100, 10% FBS/1% BSA (Sigma-
Aldrich) in PBS for 15 min at room temperature. Mouse anti-mouse H2AX 
(ser139) (Upstate clone JBW301 #05-636) and rabbit anti-mouse RAD51 (Santa 
Cruz Biotechnology H92 #sc-8349) were diluted in TBS containing 10% FBS and 
1% BSA and incubated overnight at 4 °C. Slides were then washed three times 
with PBS and subsequently incubated with 1:200 donkey anti-mouse DL 488 
(Jackson/Stratech 715-485-150) and 1:200 goat anti-rabbit Cy3 (Jackson/Stratech 
111-165-144) in TBS containing DAPI 0.2 g/ml, 10% FBS, 1% BSA for 1 h at 
room temperature in the dark. Slides were then washed five times at 10 min each 
with PBS. Slides were briefly washed in water and air-dried before mounting 
with Mowiol-DABCO and a coverslip. Cells were counted in at least five fields 
for each slide, for a total of over 100 cells per condition.
May-Grunwald Giemsa staining. 105 cells were cytospun for 5 min at 300g 
onto glass slides. Slides were then stained with May-Grunwald solution (Sigma-
Aldrich) for 3 min at room temperature. After washing in water, they were 
incubated for 20 min in Giemsa solution (Sigma-Aldrich) (1:20 in water). Slides 
were washed again in water before being mounted with Mowiol.
Nitro blue tetrazolium (NBT) reduction assay. NBT reduction assay were per-
formed to determine myeloid differentiation. 0.1% of NBT (final concentration) 
was added to the liquid culture or semi-solid MethoCult and incubated at 37 °C 
CO2 incubator for 3 h and 12 h, respectively. Cells were then washed in PBS and 
the differentiated cells were indicated by the deposition of dark blue insoluble 
formazan (NBT-positive cells) and the percentage of differentiated cells was 
counted under microscopy. At least 200 cells were counted in most cases.
shRNAs. Mouse Parp1–targeting sequences were cloned into pSuper-Retro-
Puro retroviral vector (OligoEngine). The target sequences for mouse Parp1 
gene are 5 -TAAAGAAGCTGACGGTGAA-3  (targeting the positions 
2014–2032, shParp1#A)63, 5 -GCCGCCTACTCTATCCTCA-3  (shParp1#D). 
Human HOXA9 and scrambled shRNAs were cloned in to GIPZ lentivi-
ral vector. The target sequence for the human HOXA9 gene is 5 -GTGGTT 
CTCCTCCAGTTGATA-3  (HOXA9 shRNA)44. The scrambled sequence is 5 -
GCGAAAGATGATAAGCTAA-3 .
Expression of mouse Parp1-targeting shRNA in NIH3T3 cells.  1.6 × 105 cells 
were plated in each well of six well-plates and allowed to attach for 6 h when the 
cells were transduced with 200 l of concentrated virus expressing i) the empty 
vector, ii) the scrambled or iii) shRNA targeted against mouse Parp1 and 5 g/ml 
of polybrene in a final volume of 2 ml. After 24 h, the medium was replaced fresh 
one containing 1.5 g/ml puromycin (Invitrogen) for a 3-d selection. Cells were 
then collected for RT-qPCR and western blot analysis.
Western blot analysis. Cells were collected by centrifugation, and the cell pel-
let was suspended in lysis buffer (0.02% SDS, 0.5% Triton-X, 300 mM NaCl, 
20 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM DTT, 10 mM NaF, 2 mM Na3VO4) 
containing 1× protease inhibitors (Roche) and incubated on ice for 30min. After 
centrifugation at 16,000g for 15 min at 4 °C, the supernatant containing total 
cell extract was collected and kept at −80 °C. Proteins from cell extracts were 
quantified using the OD 660 nm Assay (Pierce). 10 g of cell extracts were 
loaded on a 12% polyacrylamide gel and then electrophoretically transferred 
onto a Hybond-PVDF membrane (GE Healthcare). The membrane was incu-
bated for 1 h at room temperature in blocking buffer (TBS-T containing 8% 


























at 4 °C overnight with the primary antibody (Supplementary Table 7). After 
four washes with TBS-T, the membrane was incubated for 1 h with the horserad-
ish peroxidase (HPR)-conjugated antibody, anti-mouse or anti-rabbit (Jackson 
ImmunoResearch) diluted in blocking buffer. Antibody binding was visualized 
using the ECL Prime western blotting detection system (GE Healthcare).
Immunoprecipitation assay. Cells were lysed as above (with a reduced 
NaCl concentration to 200 mM). The 500 g of total cell lysates were incubated 
with 1 g anti-FLAG antibody at 4 °C for 12 h with rotation. Then protein 
A–conjugated beads were added to precipitate the protein complex and incu-
bated at 4 °C for 1 h with rotation. Beads were then washed five times with 
reduced NaCl cell lysis buffer and eluted with 50 l of 2% SDS-Tris buffer.
Real time Quantitative PCR. RNA was extracted by using a kit from Fermentas 
and was reverse transcribed using SuperScript III from Invitrogen. qPCR was 
performed by using SYBR Green or Taqman probes on an ABI 7900HT Fast 
Real-Time PCR System (Applied Biosystems) using primers (Supplementary 
Table 8). Gapdh was used a housekeeping gene. Relative expression levels were 
calculated using the 2- CT method (ref. 64).
In vivo plasmid end-joining assay. The in vivo plasmid end-joining assay was 
performed as described65. Briefly, a DSB is generated in the lacZ gene sequence of 
the plasmid PUC18 by EcoRI digestion. Nuclear extracts from pre-leukemic cells 
carrying the above-mentioned fusion oncoproteins were obtained by using the 
Nuclear Extraction Kit (Pierce). 2 g of PUC18 plasmid was digested with EcoRI 
(Fermentas), dephosphorylated (Fermentas), separated on a 1% agarose gel and 
extracted using a column-based method (Qiagen). 5 g of nuclear extracts were 
then incubated in NHEJ buffer (50 mM triethanolammine HCl pH7.5, 60 mM 
potassium acetate, 0.5 mM magnesium acetate, 250 M dNTPs, 10 mM ATP, 
5 mM dTT, 500 g/ml BSA) for 5 min at 37 °C. 250 ng of digested dephosphor-
ylated plasmid were then added to the reaction in 50–100 l final volume and incu-
bated for 24 h at 18 °C. The next day, the DNA was purified using a column-based 
method (Qiagen) and 30 ng were used to transform Escherichia coli and plate them 
on LB-agar plates + 160 g/ml X-Gal (Sigma-Aldrich) and 1 mM IPTG (Sigma-
Aldrich). Colonies were counted and plotted. The percentage of misrepair was 
calculated as the percentage of blue colonies versus the total number of colonies.
Homologous recombination (HR) assay. For the HR assay, 0.5 × 106 U2OS-
DR cells were plated into six-well plates. After 24 h, cells were co-transfected 
with I-SceI expression (pCBASce, 1.25 g), oncogenes of interest (1.25 g) and 
RFP constructs (0.2 g) using Lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s protocol. The percentage of GFP+ cells was measured by 
flow cytometry 3 d after transfection and normalized against the percentage 
of RFP+ cells for transfection efficiency. Relative HR efficiency was then 
normalized to empty vector.
In vivo experiments. All the experimental procedures were approved by the 
King’s College London Animal Welfare and Ethical Review Body and conform 
to the UK Home Office regulations. For all in vivo experiments, mice were dis-
tributed into their respective groups randomly. Investigators were not blinded 
to the sample identity. Mice were considered leukemic when an engraftment of 
donor cell was detected.
We established humanized models of AML1-ETO and PML-RAR  leukemia 
in sub-lethally irradiated NOD/SCID/IL2Rg−/− (NSG, 1 dose 200 RADs) by 
transplanting 2 × 106 Kasumi (intrafemoral, i.f.) and 105 NB4-LR2 or 105 THP1 
(intravenous, i.v.) cells. The day after the transplantation, mice were split into 
two groups with an equal number of males and females in each group and given 
intraperitoneal injections of vehicle (10% HBC) or olaparib (25 mg/kg in 10% 
HBC) daily for 2–4 weeks. The maximum tolerable dose was calculated by in vivo 
dose-response experiments. Mice were monitored daily until they developed 
symptoms of leukemia, when they were culled, and bone marrow, spleen and 
liver was harvested and analyzed by FACS. The engraftment of human donor 
cells was defined as CD45+CD33+ double-positive by FACS.
For Hoxa9-knockout studies, we intravenously injected 106 MLL-AF9 leuke-
mic cells (wild type or Hoxa9−/− background) together with 2 × 105 bone marrow 
rescue cells into lethally irradiated female C57Bl/6 mice (2 doses of irradiation, 
550 rads each). For drug studies, the control cohort received vehicle (10%  
2-hydroxpropyl-beta-cyclodextrin, HBC, Sigma-Aldrich) and the PARPi treat-
ment group received daily olaparib 50 mg/kg in 10% HBC for 2–4 weeks.
For mouse MLL-AF9 LSC in vivo studies involving PARPi and GSK3i, 
MLL-AF9 LSCs were pretreated in R20/20 with 4 mM LiCl or 1 M olaparib 
or a combination thereof for 3 d. Equal number 0.2 × 106 of live cells were 
transplanted into sublethally irradiated C57Bl/6 female mice. Continuous 
olaparib and Li2CO3 treatment was commenced on the day after irradiation 
and injection of cells. Mice were given 0.4% lithium carbonate–containing 
diet (Harlan Laboratory) along with olaparib by intraperitonal injection every 
other day for 4 weeks. The engraftment of mouse donor cells was defined as 
CD45.1+CD45.2− by FACS.
For in vivo experiments with primary AML samples, 105 patient-derived 
leukemic cells carrying MLL rearrangement (AML1) transduced with a firefly 
luciferase–expressing plasmid were transplanted via by i.f. injection into the 
right femur of the NSG mice. Three days after transplantation, mice were supple-
mented with 0.4% Li2CO3–containing diet and treated with olaparib as described 
above for alternative day until day 21. After day 21, mice were maintained on 5 d 
of Li2CO3 diet and alternated with 2 d of regular diet and water for 2 additional 
weeks. From day 21, the tumor burdens of the animals were detected using IVIS 
Lumina II (Caliper) with Living Image version 4.3.1 software (PerkinElmer). 
Briefly, 100 l of 30 mg/ml luciferin was injected into the animals intraperito-
neally 10 min after injection, the animals were maintained in general anaesthesia 
by isoflurane and put into the IVIS chamber for photography and detection 
of photon emission (large binning, F = 1.2, exposure time: 3 min). The tumor 
burdens were measured and quantified by the same software. The animals were 
culled when the tumor burden was 108 photons per second or higher.
Microarray and bioinformatic analysis. Expression profiles of AML1-ETO (22 
samples, cluster 13), APL (18 samples, cluster 12), MLL (11 samples, cluster 16) 
patients were obtained from GEO accession: GSE1159 (ref. 32). The data was 
supported by performing additional gene expression analysis on an independ-
ent set of published microarray data set from GSE6891 containing AML1-ETO 
(37 samples), APL (25 samples), and MLL (35 samples) leukemia samples. All 
intensity values was adjusted, normalized and summarized in log2 scale using 
Bioconductor Affy66 (background correction: rma; normalization: quantiles; 
summarization: median polish). The differential expression analyses on patients 
with leukemia exhibiting AML1-ETO and APL (PML-RAR ) against MLL were 
performed using Bioconductor (http://www.bioconductor.org/) with limma. 
P values were calculated by paired two-tailed t-test. The expression of key 
genes involved in DNA repair (Supplementary Table 2) from patients with 
leukemia expressing AML-ETO, APL (PML-RAR ) and MLL fusions was 
plotted in box-whisker plot using Prism5 software. GSEA was performed as 
described67 using published data sets44,45.
Statistical analyses. All the experimental results were analyzed using unpaired 
two-tailed Student’s t-test, one-way or two-way ANOVA, as indicated in figure 
legends. Groups that were statistically compared shared a similar variance, 
as shown in the figures. P < 0.05 was considered statistically significant. 
The log-rank test was used to compare survival curves.
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